Christine M McDonald1, Karim P Manji2, Rodrick Kisenge2, Said Aboud3, Donna Spiegelman4, Wafaie W Fawzi5, Christopher P Duggan6. 1. Division of Gastroenterology, Hepatology and Nutrition, Boston Children's Hospital, Boston, MA; 2. Departments of Pediatrics and Child Health and. 3. Microbiology and Immunology, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania; and. 4. Departments of Epidemiology, Biostatistics. 5. Departments of Epidemiology, Nutrition, and Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, MA. 6. Division of Gastroenterology, Hepatology and Nutrition, Boston Children's Hospital, Boston, MA; Nutrition, and Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, MA christopher.duggan@childrens.harvard.edu.
Abstract
BACKGROUND: Although various micronutrient regimens have been shown to prevent and treat common infectious diseases in children, the effects of daily multivitamin (MV) and/or zinc supplementation have not been widely evaluated in young African infants. OBJECTIVE: The objective was to determine whether daily supplementation of HIV-unexposed Tanzanian infants withMVs or zinc reduces the risk of infectious morbidity compared with placebo. METHODS: In a 2 × 2 factorial, double-blind, randomized controlled trial, 2400 infants who were 6 wk of age and born to HIV-negative mothers in a low-malaria setting were randomly assigned to receive daily oral supplementation of MVs (vitamin B complex and vitamins C and E), zinc, zinc + MVs, or placebo for 18 mo. Morbidity was assessed by study nurses at monthly visits and by physicians every 3 mo and/or when the child was acutely ill. RESULTS: No significant differences were found in the percentage of nurse visits during which diarrhea, cough, or any other symptom were reported throughout the previous month when receiving either zinc or MVs. However, physician diagnoses of all types of diarrhea (RR = 0.88; 95% CI: 0.81, 0.96; P = 0.003), dysentery (RR = 0.84; 95% CI: 0.74, 0.95; P = 0.006), and acute upper respiratory infection (RR = 0.92; 95% CI: 0.88, 0.97; P = 0.0005) were significantly lower for infants supplemented with zinc than for those who did not receive zinc. Among the 2360 infants for whom vital status was obtained, there was a nonsignificant increase in all-cause mortality among infants who received zinc (HR = 1.80; 95% CI: 0.98, 3.31; P = 0.06) compared with those who did not receive zinc. MVs did not alter the rates of any recorded physician diagnoses or mortality. Neither zinc nor MVs reduced hospitalizations or unscheduled outpatient visits. CONCLUSIONS: Daily zinc supplementation of Tanzanian infants beginning at the age of 6 wk may lower the burden of diarrhea and acute upper respiratory infections, but provision of MVs using the regimen in this trial did not confer additional benefit. This trial was registered at clinicaltrials.gov as NCT00421668.
RCT Entities:
BACKGROUND: Although various micronutrient regimens have been shown to prevent and treat common infectious diseases in children, the effects of daily multivitamin (MV) and/or zinc supplementation have not been widely evaluated in young African infants. OBJECTIVE: The objective was to determine whether daily supplementation of HIV-unexposed Tanzanian infants with MVs or zinc reduces the risk of infectious morbidity compared with placebo. METHODS: In a 2 × 2 factorial, double-blind, randomized controlled trial, 2400 infants who were 6 wk of age and born to HIV-negative mothers in a low-malaria setting were randomly assigned to receive daily oral supplementation of MVs (vitamin B complex and vitamins C and E), zinc, zinc + MVs, or placebo for 18 mo. Morbidity was assessed by study nurses at monthly visits and by physicians every 3 mo and/or when the child was acutely ill. RESULTS: No significant differences were found in the percentage of nurse visits during which diarrhea, cough, or any other symptom were reported throughout the previous month when receiving either zinc or MVs. However, physician diagnoses of all types of diarrhea (RR = 0.88; 95% CI: 0.81, 0.96; P = 0.003), dysentery (RR = 0.84; 95% CI: 0.74, 0.95; P = 0.006), and acute upper respiratory infection (RR = 0.92; 95% CI: 0.88, 0.97; P = 0.0005) were significantly lower for infants supplemented with zinc than for those who did not receive zinc. Among the 2360 infants for whom vital status was obtained, there was a nonsignificant increase in all-cause mortality among infants who received zinc (HR = 1.80; 95% CI: 0.98, 3.31; P = 0.06) compared with those who did not receive zinc. MVs did not alter the rates of any recorded physician diagnoses or mortality. Neither zinc nor MVs reduced hospitalizations or unscheduled outpatient visits. CONCLUSIONS: Daily zinc supplementation of Tanzanian infants beginning at the age of 6 wk may lower the burden of diarrhea and acute upper respiratory infections, but provision of MVs using the regimen in this trial did not confer additional benefit. This trial was registered at clinicaltrials.gov as NCT00421668.
Authors: Robert E Black; Cesar G Victora; Susan P Walker; Zulfiqar A Bhutta; Parul Christian; Mercedes de Onis; Majid Ezzati; Sally Grantham-McGregor; Joanne Katz; Reynaldo Martorell; Ricardo Uauy Journal: Lancet Date: 2013-06-06 Impact factor: 79.321
Authors: Zulfiqar A Bhutta; Jai K Das; Arjumand Rizvi; Michelle F Gaffey; Neff Walker; Susan Horton; Patrick Webb; Anna Lartey; Robert E Black Journal: Lancet Date: 2013-06-06 Impact factor: 79.321
Authors: Saskia J M Osendarp; Mathuram Santosham; Robert E Black; M A Wahed; Joop M A van Raaij; George J Fuchs Journal: Am J Clin Nutr Date: 2002-12 Impact factor: 7.045
Authors: Christopher Duggan; Karim P Manji; Roland Kupka; Ronald J Bosch; Said Aboud; Rodrick Kisenge; James Okuma; Wafaie W Fawzi Journal: Am J Clin Nutr Date: 2012-11-07 Impact factor: 7.045
Authors: Mohammad Yawar Yakoob; Evropi Theodoratou; Afshan Jabeen; Aamer Imdad; Thomas P Eisele; Joy Ferguson; Arnoupe Jhass; Igor Rudan; Harry Campbell; Robert E Black; Zulfiqar A Bhutta Journal: BMC Public Health Date: 2011-04-13 Impact factor: 3.295
Authors: Wolf-Peter Schmidt; Benjamin F Arnold; Sophie Boisson; Bernd Genser; Stephen P Luby; Mauricio L Barreto; Thomas Clasen; Sandy Cairncross Journal: Int J Epidemiol Date: 2011-12 Impact factor: 7.196
Authors: Emily R Smith; Lindsey M Locks; Karim P Manji; Christine M McDonald; Roland Kupka; Rodrick Kisenge; Said Aboud; Wafaie W Fawzi; Christopher P Duggan Journal: J Pediatr Date: 2017-12 Impact factor: 4.406
Authors: Lindsey M Locks; Karim P Manji; Roland Kupka; Enju Liu; Rodrick Kisenge; Christine M McDonald; Said Aboud; Molin Wang; Wafaie W Fawzi; Christopher P Duggan Journal: J Pediatr Date: 2016-11-07 Impact factor: 4.406
Authors: Mia M Blakstad; Emily R Smith; Analee Etheredge; Lindsey M Locks; Christine M McDonald; Roland Kupka; Rodrick Kisenge; Said Aboud; David Bellinger; Christopher R Sudfeld; Wafaie W Fawzi; Karim Manji; Christopher P Duggan Journal: J Pediatr Date: 2018-12-14 Impact factor: 4.406
Authors: Christine M McDonald; Karim P Manji; Kerri Gosselin; Hao Tran; Enju Liu; Rodrick Kisenge; Said Aboud; Wafaie W Fawzi; Andrew T Gewirtz; Christopher P Duggan Journal: Am J Clin Nutr Date: 2016-04-27 Impact factor: 7.045
Authors: Lindsey M Locks; Karim P Manji; Christine M McDonald; Roland Kupka; Rodrick Kisenge; Said Aboud; Molin Wang; David C Bellinger; Wafaie W Fawzi; Christopher P Duggan Journal: Matern Child Nutr Date: 2016-05-18 Impact factor: 3.092
Authors: Analee J Etheredge; Karim Manji; Mark Kellogg; Hao Tran; Enju Liu; Christine M McDonald; Rodrick Kisenge; Said Aboud; Wafaie Fawzi; David Bellinger; Andrew T Gewirtz; Christopher P Duggan Journal: J Pediatr Gastroenterol Nutr Date: 2018-06 Impact factor: 2.839
Authors: Lindsey M Locks; Karim P Manji; Christine M McDonald; Roland Kupka; Rodrick Kisenge; Said Aboud; Molin Wang; Wafaie W Fawzi; Christopher P Duggan Journal: Am J Clin Nutr Date: 2016-01-27 Impact factor: 7.045